AGTC to Participate at Upcoming Investor Conferences
03 August 2021 - 6:05AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare retinal diseases, today announced that management will be
participating in the following virtual investor conferences:
- BTIG Virtual Biotechnology
Conference (August 9, 2021)Sue Washer, President &
Chief Executive Officer, will participate in a fireside chat at
1:30 p.m. ET on Monday, August 9, 2021. Participants interested in
listening to the live fireside chat may contact their BTIG
conference representative.
- 2021 Wedbush PacGrow
Healthcare Virtual Conference (August 10-11, 2021)Ms.
Washer will participate in a panel discussion entitled: “Only Have
Eyes For You - Ophthalmic Gene Therapy” at 8:00 a.m. ET on
Wednesday, August 11, 2021.
- H.C. Wainwright
Ophthalmology Virtual Conference (August 17, 2021)A
presentation by Ms. Washer will be available to view on-demand
beginning Tuesday, August 17, 2021 at 7:00 a.m. ET through the
entirety of the conference.
Audio webcasts of the presentations at the
Wedbush and H.C. Wainwright conferences can be accessed by visiting
http://ir.agtc.com/events-and-presentations. Replays will be
available on the Company's website following the events.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies that address
real patient needs. AGTC’s most advanced clinical programs leverage
its best-in-class technology platform to potentially improve vision
for patients with an inherited retinal disease. AGTC has active
clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build
on the Company’s industry leading AAV manufacturing technology and
scientific expertise. AGTC is advancing multiple important pipeline
candidates to address substantial unmet clinical need in
optogenetics, otology and CNS disorders. In recent years AGTC has
entered into strategic partnerships with companies including
Otonomy, Inc., a biopharmaceutical company dedicated to the
development of innovative therapeutics for neurotology, and Bionic
Sight, LLC, an innovator in the emerging field of optogenetics and
retinal coding.
IR/PR CONTACTS: David
Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768
or (646) 871-8485david.carey@finnpartners.com or
glenn.silver@finnpartners.com
Corporate Contact:Stephen
PotterChief Business OfficerApplied Genetic Technologies
CorporationT: (617) 413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2024 to May 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Applied Genetic Technologies Corporation (NASDAQ): 0 recent articles
More News Articles